-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
-
Summary
-
Biocryst Pharmaceuticals Inc quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2015 to Q1 2025.
- Biocryst Pharmaceuticals Inc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending March 31, 2025 was $93.4M, a 54.2% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)